Novavax Announces Positive Phase One Data For Potential COVID-19 Vaccine

Novavax, a Gaithersburg-based biotech company, announced Tuesday encouraging results from its potential COVID-19 vaccine. The Phase 1 portion of the Phase 1/2 clinical trial evaluated two doses of Novavax’ COVID-19 vaccine across two dose levels in 131 healthy adults ages 18-59 years. (WJZ-TV)

Read Full Article